133804-52-1

Basic information

• Product Name: 2-[1,4]Diazepan-1-yl-5-propyl-benzenesulfonic acid
• Synonyms: 2-[1,4]Diazepan-1-yl-5-propyl-benzenesulfonic acid
• CAS NO: 133804-52-1
• Molecular Formula: C14H22N2O3S
• Molecular Weight: 298.4
• Product Categories: pharmacetical
• Mol File: 133804-52-1.mol

Chemical Properties

• Appearance: /
• Density: 1.205g/cm³
• Refractive Index: 1.556
• CAS DataBase Reference: 2-[1,4]Diazepan-1-yl-5-propyl-benzenesulfonic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[1,4]Diazepan-1-yl-5-propyl-benzenesulfonic acid(133804-52-1)
• EPA Substance Registry System: 2-[1,4]Diazepan-1-yl-5-propyl-benzenesulfonic acid(133804-52-1)

Safety Data

• Hazardous Substances Data: 133804-52-1(Hazardous Substances Data)

Usage

General Description

2-[1,4]Diazepan-1-yl-5-propyl-benzenesulfonic acid is a chemical compound that belongs to the class of benzenesulfonic acids. It has a diazepan-1-yl group attached to the 2 position and a propyl group attached to the 5 position of the benzene ring. 2-[1,4]Diazepan-1-yl-5-propyl-benzenesulfonic acid may have potential biological activities due to the presence of the diazepan-1-yl group, which is a seven-membered heterocyclic ring with various pharmacological properties. The benzenesulfonic acid moiety could also affect the compound's solubility and stability. Understanding the chemical properties and biological activities of 2-[1,4]Diazepan-1-yl-5-propyl-benzenesulfonic acid could be important for further research and potential applications in the pharmaceutical or chemical industry.

InChI:InChI=1/C14H22N2O3S/c1-2-4-12-5-6-13(14(11-12)20(17,18)19)16-9-3-7-15-8-10-16/h5-6,11,15H,2-4,7-10H2,1H3,(H,17,18,19)

Upstream product

• 505-66-8 1,4-Diazacycloheptane 
• 133804-56-5 2-fluoro-5-n-propylbenzenesulfonic acid 

Relevant articles and documents

REMEDIES AND/OR PREVENTIVES FOR DIABETIC ISCHEMIC HEART DISEASES

An agent for therapeutic and /or prophylactic treatment of heart failure or arrhythmia in diabetic ischemic heart disease, which comprises as an active ingredient an aminobenzenesulfonic acid derivative represented by the following general formula (I): (wherein R1 represents, for example, hydrogen atom; R2 represents, for example, hydrogen atom; and n represents an integer of from 1 to 4) or a salt thereof, or a hydrate thereof or a solvate thereof, and an agent for therapeutic and /or prophylactic treatment of diabetic ischemic heart disease wherein said agent improves a cardiac dysfunction in diabetic ischemic heart disease.

PHARMACEUTICAL PREPARATIONS CONTAINING AMINOBENZENE-SULFONIC ACID DERIVATIVES AS THE ACTIVE INGREDIENT

A stable pharmaceutical preparation containing an aminobenzenesulfonic acid derivative represented by the following formula (I) known as a therapeutic agent for cardiac insufficiency: or a salt thereof, or a hydrate thereof or a solvate thereof as an active ingredient, wherein each production of substance A having a retention time of about 6.4 minutes in a high performance liquid chromatography, substance B having a retention time of about 15.6 minutes in the high performance liquid chromatography, and substance C having about 22.8 minutes in the high performance liquid chromatography is substantially suppressed, wherein said high performance liquid chromatography is performed at a controlled flow rate for elution so as to give a retention time of about 7 minutes of said active ingredient by using an ultraviolet absorptiometer at 220 nm, an octylsilylated silica gel packed column (4 mm x 250 mm) at 40°C, and a mobile phase prepared by dissolving 7.8 g of sodium dihydrogenphosphate dihydrate in 1000 mL of a mixture of water/acetonitrile (6:1) after said pharmaceutical preparation is extracted with a diluent prepared by dissolving 7.8 g of sodium dihydrogenphosphate dihydrate in 1000 mL of a mixture of water/acetonitrile (6:1) and adjusting a pH to 7.0 with addition of 8 mol/L sodium hydroxide solution.

Remedies and/or preventives for nervous system disorders

A therapeutic and/or prophylactic agent for nervous system disorder comprising as the active ingredient substances having an effect of improving calcium ion uptake of cardiac sarcoplasmic reticulum and/or an effect of inhibiting overaccumulation of intracellular calcium ions is offered. Preferably, the therapeutic and/or prophylactic agent for disease selected from the group consisting of cerebrovascular disease, traumatic head injury and postencephalitis and the therapeutic and/or prophylactic agent for disease selected from the group consisting of dementia and neuronal degeneration disease are offered.

Aminobenzenesulfonic acid derivatives

There is disclosed an aminobenzenesulfonic acid derivative of the formula: STR1 wherein R1 represents hydrogen atom, a C1 -C6 alkyl group, a C3 -C7 cycloalkyl group, a C1 -C4 hal